Time filter

Source Type

Ozenne V.,Service dHepatologie | Gervais A.,Service des Maladies Infectieuses | Peytavin G.,Laboratoire Of Toxicologie Et Pharmacocinetique | Castelnau C.,Service dHepatologie | And 2 more authors.
Hepato-Gastroenterology | Year: 2011

Sorafenib prolongs survival of patients with unresectablehepatocellular carcinoma (HCC). It is likely to be used in human immunodeficiency virus (HIV) infected patients. Interactions between sorafenib and highly active antiretroviral therapy (HAART) have not been studied yet. We report a case of serious adverse effects in anHIV-1 patient co-infected with HBV. © H.G.E. Update Medical Publishing S.A. Source

Antonini T.M.,Center Hepato Biliaire | Antonini T.M.,University Paris - Sud | Furlan V.,AP HP | Furlan V.,Center Hepato Biliaire | And 27 more authors.
AIDS | Year: 2013

We report, for the first time, the outcome of anti-hepatitis C virus (HCV) triple therapy with telaprevir in an HIV/HCV co-infected transplanted patient. After liver transplantation, the patient experienced a severe HCV recurrence with fibrosing cholestatic hepatitis, and anti-HCV therapy with pegylated interferon alpha 2a, ribavirin and telaprevir was initiated. A sustained virological response was achieved after 48 weeks of anti-HCV therapy. Drug-drug interactions between antiretroviral therapy, immunosuppressive agents and anti-HCV therapy could be managed. © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins. Source

Boulamery A.,Jean Moulin University Lyon 3 | Venisse N.,Laboratoire Of Toxicologie Et Pharmacocinetique | Guellec C.L.,University of Tours
Therapie | Year: 2011

Level of Evidence for Therapeutic Drug Monitoring of Teicoplatin. Teicoplanin is a glycopeptid antibiotic used for treatment of serious infections caused by Gram+ bacteriae. The treatment scheme corresponds to an initial loading dose followed by maintenance dose. High interindividual pharmacokinetic variability and strong relation between high through concentrations, dose and clinical success, support the need of therapeutic drug monitoring using through concentrations. Achieving through concentrations ≥10-15 mg/L or ≥20-40 mg/L, regarding the measurement method and the infection severity, is recommended to increase clinical success rate. The level of proof of therapeutic drug monitoring is evaluated: "necessary". ©Socié té Française de Pharmacologie et de Thérapeutique. Source

Aslangul E.,University of Paris Descartes | Assoumou L.,French Institute of Health and Medical Research | Assoumou L.,University Pierre and Marie Curie | Bittar R.,Biochimie des Maladies Metaboliques | And 14 more authors.
AIDS | Year: 2010

BACKGROUND: HIV infection and its treatment with protease inhibitors, especially when boosted with ritonavir, can cause lipid disorders. Statins, with the exception of fluvastatin, pravastatin and rosuvastatin, interact with protease inhibitor metabolism via CYP450. Pravastatin is recommended for patients with protease inhibitor-associated dyslipidemia. Rosuvastatin is the statin most effective on low-density lipoprotein cholesterol (LDL-c) in non-HIV patients. METHODS: HIV-1-infected patients treated with boosted protease inhibitor were randomized to receive either rosuvastatin 10 mg/day or pravastatin 40 mg/day for dyslipidemia (LDL-c >4.1 mmol/l and triglycerides <8.8 mmol/l). The percentage change in LDL-c, triglyceride and high-density lipoprotein-cholesterol levels, measured in a central laboratory, was determined after 45 days of statin treatment. RESULTS: Eighty-eight patients were randomized and 83 took the study drugs, 41 rosuvastatin and 42 pravastatin. The median duration of prior antiretroviral treatment was 9 years. At baseline, the median LDL-c level was 4.93 mmol/l, the triglyceride level 2.29 mmol/l, and the high-density lipoprotein-cholesterol level 1.27 mmol/l. The median percentage changes in the rosuvastatin and pravastatin arms were-37 and-19% for LDL-c (P < 0.001), respectively, and-19 and-7% for triglycerides (P = 0.035), respectively. The change in the high-density lipoprotein-cholesterol level was not significantly different between the two arms. None of the four severe adverse events was attributed to the statins; in particular, there were no renal, hepatic or muscular events. CONCLUSION: Rosuvastatin 10 mg/day was more effective than pravastatin 40 mg/day on LDL-c and triglyceride levels in HIV-1-infected patients receiving a boosted protease inhibitor. © 2010 Wolters Kluwer Health | Lippincott Williams & Wilkins. Source

Discover hidden collaborations